Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19.

Buryachkovskaya, Liudmila; Lomakin, Nikita; Melkumyants, Arthur; Docenko, Julia; Serebruany, Victor

Buryachkovskaya, Liudmila; Lomakin, Nikita; Melkumyants, Arthur; Docenko, Julia; Serebruany, Victor.

Buryachkovskaya L; National Cardiology Research Center, 121552 Moscow, Russia.
Lomakin N; Cardiology Division, Central Clinical Hospital of Presidential Administration, 121359 Moscow, Russia.
Melkumyants A; National Cardiology Research Center, 121552 Moscow, Russia.
Docenko J; Institute of Physics and Technology, 141701 Moscow, Russia.
Serebruany V; National Cardiology Research Center, 121552 Moscow, Russia.

Rev Cardiovasc Med ; 22(3): 549-551, 2021 09 24.

Article in English | MEDLINE | ID: covidwho-1439021

ABSTRACT

ABSTRACT

No abstract present.

Subject(s)

Anti-Inflammatory Agents/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Blood Platelets/drug effects; COVID-19 Drug Treatment; Erythrocytes/drug effects; Leukocytes/drug effects; Anti-Inflammatory Agents/adverse effects; Antibodies, Monoclonal, Humanized/adverse effects; Blood Platelets/ultrastructure; COVID-19/blood; COVID-19/diagnosis; Case-Control Studies; Erythrocytes/ultrastructure; Humans; Leukocytes/ultrastructure; Microscopy, Electron, Scanning; Prospective Studies; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Platelets / Erythrocytes / Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment / Leukocytes / Anti-Inflammatory Agents Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Rev Cardiovasc Med Journal subject: Vascular Diseases / Cardiology Year: 2021 Document Type: Article Affiliation country: J.rcm2203065

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google